Valneva Austria GmbH clinical trials

Acquired by Valneva, May 28, 2013 · source ↗

The registry lists 44 studies whose lead sponsor is Valneva Austria GmbH. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 44 of 44. All Valneva studies →

• VLA1553-403 Pregnancy Surveillance StudyEnrolling by invitationNCT07414524

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilEnrolling by invitationNCT07347002

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsCompletedNCT06106581Phase 2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruitingNCT07254702

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)Active, not recruitingNCT04838444Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy AdultsCompletedNCT06334393Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruitingNCT07163845

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy ChildrenWithdrawnNCT07133178Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)WithdrawnNCT06028841Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00594958Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00604708Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedNCT00605085Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy AdultsCompletedNCT04786444Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Safety and Immunogenicity of VLA2001 Adults Aged ≥56 YearsCompletedNCT04956224Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in AdultsCompletedNCT04546724Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 InfectionCompletedNCT05364242Phase 2/3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222CompletedNCT04864561Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• COVID-19 Paediatric VLA2001-321 StudyWithdrawnNCT05298644Phase 2/3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy SubjectsCompletedNCT04671017Phase 1/2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedNCT01041573Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701CompletedNCT03576183Phase 2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesCompletedNCT01047839Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedNCT01246479Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy VolunteersCompletedNCT03382964Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy AdultsCompletedNCT03425149Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II StudyCompletedNCT02316470Phase 2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted after Valneva Austria GmbH became part of Valneva

• Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedNCT00776230Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43CompletedNCT01563263Phase 2/3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Safety Surveillance After Immunization With IXIAROCompletedNCT01335412

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedNCT01296360Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84CompletedNCT01296386Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51CompletedNCT00596102

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00595465Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595309Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440CompletedNCT00596271Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00595790Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595270Phase 3

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Virological Response Study of the HCV Vaccine IC41CompletedNCT00601770Phase 2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Immune Response in IXIARO Batch JEV09L37 Recipients Before and After RevaccinationWithdrawnNCT01559831Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47CompletedNCT00873431Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Study Assessing Immunogenicity and Safety of IC43 In Intensive Care PatientsCompletedNCT00876252Phase 2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide VaccineCompletedNCT00602784Phase 2

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy VolunteersCompletedNCT00778388Phase 1

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva

• This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedNCT01158599Phase 4

  Sponsor listed in the registry: Valneva Austria GmbH · First submitted before Valneva Austria GmbH became part of Valneva